Launch Date
07/24/2023 at 4:00 am EST
Credit Amount
0.5
Credit Expires
12/31/2025
Idiopathic hypersomnia (IH) is an elusive disease state with a significant impact on quality of life (QoL). Clinicians often fail to recognize how this impact on QoL affects both patient and family, and how IH disrupts one’s ability to live a full life. Unfortunately, clinician’s struggle to apply novel treatments into practice and lack guidance as recent AASM guidelines to not include most up-to-date data for the optimal treatment of IH. Additionally, in August 2021, lower-sodium oxybate (LXB) was the first treatment approved for IH, however, understanding of this novel treatment is still lacking.
In this CMEO BriefCase entitled, Choosing Treatment: Matching Needs to Therapy, expert faculty will engage in a case-based discussion on how to best utilize the latest efficacy and safety data to integrate novel therapies into clinical practice to mitigate the impact of IH.
Utilize the latest efficacy and safety data to integrate novel therapies into clinical practice to mitigate the impact of IH.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Sleep specialists, primary care physicians, pulmonologists, neurologists, psychiatrists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Thorpy reports the following financial relationships:
Advisory Board/Consultant: Alkermes; Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Ltd.; Takeda Pharmaceuticals U.S.A., Inc.; and XWPharma Ltd.
Dr. Auger has no financial relationships to disclose.
Ms. Hasan has no financial relationships to disclose.
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at 877.CME.PROS (877.263.7767).
BC-092-072423-43